Skip to content
The Policy VaultThe Policy Vault

Augtyro — Blue Cross Blue Shield of Kansas

Metastatic ROS1-positive non-small cell lung cancer (NSCLC)

Preferred products

  • Rozlytrek
  • Xalkori

Initial criteria

  • Target Agent(s) will be approved when ALL of the following are met (same general PA criteria apply) including verification of labeled or compendia-supported indication, age, testing, therapy use criteria, and preferred vs non-preferred logic.